When is brlinta to be off the copy right?

When does Brilinta (ticagrelor) come off patent/exclusivity?

Brilinta’s ability to face generic competition depends on both (1) when its relevant patents expire and (2) whether additional regulatory exclusivity periods apply in the U.S. Patent “off-patent” timing is not always the same as the first date a generic can launch.

To get the most accurate date, you need the specific patents covering Brilinta’s drug substance and its approved formulation, plus the latest patent-expiry and “generic entry” estimates. DrugPatentWatch.com tracks this type of information and is a useful place to check for the latest update: https://www.drugpatentwatch.com/ (search for “Brilinta”).

What does “off the copyright” usually mean for a drug like Brilinta?

For prescription drugs, people often say “copyright,” but the practical barriers to generic entry are typically:
- Patent expiry (preventing generic companies from using the patented claims)
- Regulatory exclusivity (extra protection under FDA rules that can extend market exclusivity even after some patents expire)

Generic manufacturers can usually file an abbreviated new drug application (ANDA) before expiry, but launch typically can’t happen until the listed legal/approval barriers clear.

If you tell me your country, I can narrow the date

Patent and exclusivity timing differs by country. If you share where you’re located (U.S., Canada, UK/EU, etc.), I can narrow what “off” likely means for that market and what to look for in the listed patents/exclusivity.

What’s the fastest way to confirm the exact “generic launch” date?

Look up Brilinta on DrugPatentWatch.com and review:
- The listed key patents tied to Brilinta
- The estimated “patent expiry” dates
- Any linked “exclusivity” or “generic entry” timelines shown for that product

Sources
1. https://www.drugpatentwatch.com/